Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Toxicities of hemoglobin solutions: in search of in-vitro and in-vivo model systems.

Buehler PW, Alayash AI.

Transfusion. 2004 Oct;44(10):1516-30. Review.

PMID:
15383027
2.

First-generation blood substitutes: what have we learned? Biochemical and physiological perspectives.

Alayash AI, D'Agnillo F, Buehler PW.

Expert Opin Biol Ther. 2007 May;7(5):665-75. Review.

PMID:
17477804
3.

Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.

EFSA GMO Panel Working Group on Animal Feeding Trials..

Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Review.

PMID:
18328408
4.

The development of hemoglobin solutions as red cell substitutes.

Ogden JE, Parry ES.

Int Anesthesiol Clin. 1995 Winter;33(1):115-29. Review.

PMID:
7635553
5.
6.

Review of hemoglobin-vesicles as artificial oxygen carriers.

Sakai H, Sou K, Horinouchi H, Kobayashi K, Tsuchida E.

Artif Organs. 2009 Feb;33(2):139-45. doi: 10.1111/j.1525-1594.2008.00698.x. Review.

PMID:
19178458
7.

Hemoglobin-based oxygen carriers: From mechanisms of toxicity and clearance to rational drug design.

Buehler PW, D'Agnillo F, Schaer DJ.

Trends Mol Med. 2010 Oct;16(10):447-57. doi: 10.1016/j.molmed.2010.07.006. Review.

PMID:
20708968
8.

Oxygen therapeutics--current concepts.

Hill SE.

Can J Anaesth. 2001 Apr;48(4 Suppl):S32-40.

PMID:
11336435
9.

Artificial oxygen carriers as red blood cell substitutes: a selected review and current status.

Kim HW, Greenburg AG.

Artif Organs. 2004 Sep;28(9):813-28. Review.

PMID:
15320945
10.

Artificial blood: current status of hemoglobin solutions.

Gould SA, Sehgal LR, Sehgal HL, Moss GS.

Crit Care Clin. 1992 Apr;8(2):293-309. Review.

PMID:
1568141
11.

Civilian uses of hemoglobin-based oxygen carriers.

Greenburg AG, Kim HW.

Artif Organs. 2004 Sep;28(9):795-9. Review.

PMID:
15320942
12.
13.

Preclinical biology of recombinant human hemoglobin, rHb1.1.

Zuckerman SH, Doyle MP, Gorczynski R, Rosenthal GJ.

Artif Cells Blood Substit Immobil Biotechnol. 1998 May;26(3):231-57. Review.

PMID:
9635118
14.

Clinical development of human polymerized hemoglobin as a blood substitute.

Gould SA, Moss GS.

World J Surg. 1996 Nov-Dec;20(9):1200-7. Review.

PMID:
8864082
15.

Clinical contextualization and the assessment of adverse events in HBOC trials.

Greenburg AG, Pitman A, Pearce B, Kim HW.

Artif Cells Blood Substit Immobil Biotechnol. 2008;36(6):477-86. doi: 10.1080/10731190802554000.

PMID:
19039687
16.

Evaluating new red cell substitutes: a critical analysis of toxicity models.

Greenburg AG, Kim HW.

Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):575-9.

PMID:
1391480
17.

Safety and efficacy of o-raffinose cross-linked human hemoglobin (Hemolink) in cardiac surgery.

Cheng DC.

Can J Anaesth. 2001 Apr;48(4 Suppl):S41-8. Review.

PMID:
11336436
18.

Recent developments in hemoglobin-based oxygen carriers--an update on clinical trials.

Carmichael FJ.

Transfus Apher Sci. 2001 Feb;24(1):17-21. Review.

PMID:
11515606
19.

A preclinical screening test for modified hemoglobin to bridge the gap between animal safety studies and use in human.

Chang TM, Lister C.

Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):565-73.

PMID:
1391479
20.

Prevention of side effects by hemoglobin solutions; the selection of optimal test models, especially concerning thrombogenicity.

Bakker JC, Bleeker WK, Den Boer PJ, Biessels PT, Agterberg J, Rigter G, Holthuis JC, Mertens K.

Artif Cells Blood Substit Immobil Biotechnol. 1994;22(3):577-85.

PMID:
7994377
Items per page

Supplemental Content

Support Center